UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 8-K
___________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 3, 2017
___________________
AVADEL PHARMACEUTICALS PLC
(Exact name of registrant as specified in its charter)
___________________
Ireland
(State or Other Jurisdiction
of Incorporation) | 000-28508
(Commission File Number) | Applied For (I.R.S. Employer
Identification No.) |
| | Block 10-1
Blanchardstown, Corporate Park, Ballycoolin Dublin 15, Ireland
(Address of Principal Executive Offices) | | Not Applicable (Zip Code) | |
Registrant's telephone number, including area code: +353 1 485 1200
___________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On January 3, 2017, Avadel Pharmaceuticals plc issued a press release announcing that Flamel Technologies S.A. (the predecessor of Avadel Pharmaceuticals plc) completed its cross-border merger with and into its wholly-owned Irish subsidiary, Avadel Pharmaceuticals plc (NASDAQ:AVDL) ("Avadel"), effective January 1, 2017, with Avadel surviving the merger as the public holding company. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
On January 3, 2017, Avadel Pharmaceuticals plc issued a press release announcing the appointment of Gregory J. Divis as Executive Vice President and Chief Commercial Officer. A copy of the press release is furnished as Exhibit 99.2 to this current report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| 99.1 | | Press release of Flamel Technologies S.A. dated as of January 3, 2017. |
| 99.2 | | Press release of Flamel Technologies S.A. dated as of January 3, 2017. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AVADEL PHARMACEUTICALS PLC
By: /s/ Phillandas T. Thompson
Phillandas T. Thompson
Senior Vice President, General Counsel and Corporate Secretary
Date: January 4, 2017
Exhibit Index
